Wang Shanshan, Meng Ying, Li Chengyi, Qian Min, Huang Rongqin
Department of Pharmaceutics, School of Pharmacy, Key Laboratory of Smart Drug Delivery, Ministry of Education, Fudan University, Shanghai 201203, China.
Nanomaterials (Basel). 2015 Dec 28;6(1):3. doi: 10.3390/nano6010003.
Glioma has been considered to be the most frequent primary tumor within the central nervous system (CNS). The complexity of glioma, especially the existence of the blood-brain barrier (BBB), makes the survival and prognosis of glioma remain poor even after a standard treatment based on surgery, radiotherapy, and chemotherapy. This provides a rationale for the development of some novel therapeutic strategies. Among them, receptor-mediated drug delivery is a specific pattern taking advantage of differential expression of receptors between tumors and normal tissues. The strategy can actively transport drugs, such as small molecular drugs, gene medicines, and therapeutic proteins to glioma while minimizing adverse reactions. This review will summarize recent progress on receptor-mediated drug delivery systems targeting to glioma, and conclude the challenges and prospects of receptor-mediated glioma-targeted therapy for future applications.
胶质瘤被认为是中枢神经系统（CNS）中最常见的原发性肿瘤。胶质瘤的复杂性，尤其是血脑屏障（BBB）的存在，使得即使经过基于手术、放疗和化疗的标准治疗，胶质瘤的生存率和预后仍然很差。这为一些新型治疗策略的开发提供了理论依据。其中，受体介导的药物递送是一种利用肿瘤组织与正常组织之间受体差异表达的特异性模式。该策略可以将小分子药物、基因药物和治疗性蛋白质等药物主动转运至胶质瘤，同时将不良反应降至最低。本文综述了靶向胶质瘤的受体介导药物递送系统的最新进展，并总结了受体介导的胶质瘤靶向治疗在未来应用中的挑战和前景。
